

GLAXOSMITHKLINE PLC  
Form 6-K/A  
May 30, 2008

**FORM 6-K/A**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending May 30, 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

--

This announcement replaces the original announcement released on 29/05/08.

The total number of shares in issue (excluding Treasury shares) should read

5,340,534,764

and not

5,330,534,764

shares

as previously stated

. All other details remain unchanged.

The amended text appears below

.

GlaxoSmithKline plc (the 'Company') announces that in accordance with the

authority granted by shareholders at the Company's Annual General Meeting on 21 May 2008

it purchased

2,770,000

of its Ordinary shares of 25 pence each ('shares')

) on 29 May 2008 at a price of 1,110.04

pence per share.

The shares will be cancelled.

Following the cancellation of these shares, the Company holds 484,194,158 of its shares in Treasury, representing

9.08

% of

the total voting rights in the

Company.

<R>

The Company

has

5,340,534,764

shares in issue (excluding Treasury shares). This number represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Financial Services Authority's Disclosure and Transparency Rules.

</R>

This announcement does not constitute, or form part of, an offer or any solicitation of an offer to purchase or subscribe for securities in any jurisdiction and is in conformity with the Financial Services Authority's Disclosure and Transparency Rules.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: May 30, 2008

By: VICTORIA WHYTE  
-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc